Provided are pharmaceutical compositions comprising glycopyrrolate, a beta2-adrenergic agonist, and optionally a corticosteroid. Preferred beta2-adrenergic agonists include indacaterol, formoterol, vilanterol, carmoterol and olodaterol. Preferred corticosteroids include fluticasone and mometasone. Particularly preferred compositions consist of glycopyrrolate, formoterol fumarate dihydrate and fluticasone furoate； glycopyrrolate, vilanterol trifenatate and fluticasone furoate； or glycopyrrolate and olodaterol hydrochloride monohydrate. The compositions can be used in the treatment of respiratory, inflammatory or obstructive airway diseases.
